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Disease-causing mutations occur in genes for
aminoacyl tRNA synthetases. That some muta-
tions are dominant suggests a gain of function.
Native tRNA synthetases, such as tyrosyl-tRNA
synthetase (TyrRS) and tryptophanyl-tRNA syn-
thetase, catalyze aminoacylation and are also
procytokines that are activated by natural frag-
mentation. In principle, however, gain-of-func-
tion phenotypes could arise from mutational
activation of synthetase procytokines. From
crystal structure analysis, we hypothesized
that a steric block of a critical Glu-Leu-Arg
(ELR) motif in full-length TyrRS suppresses the
cytokine activity of a natural fragment. To test
this hypothesis, we attempted to uncover ELR
in the procytokine by mutating a conserved
tyrosine (Y341) that tethers ELR. Site-specific
proteolytic cleavage and small-angle X-ray
scattering established subtle opening of the
structure by the mutation. Strikingly, four differ-
ent assays demonstrated mutational activation
of cytokine functions. The results prove the
possibilities for constitutive gain-of-function
mutations in tRNA synthetases.
INTRODUCTION
Aminoacyl tRNA synthetases (AARS) are a group of 20
enzymes, one for each amino acid, which catalyze the first
step of protein synthesis by aminoacylation of tRNAs. In-
terestingly, both recessive [1, 2] and dominant [3–10] mu-
tations in genes for tRNA synthetases have causal associ-
ations with diseases in humans and mice. These causal
associations of disease with mutations in synthetases
have, in some instances, been shown to not be associated
with defects in aminoacylation activity [3, 10, 11]. Alterna-
tively, the connections with human diseases may reflectChemistry & Biology 14, 1323–13a long evolution, during which the enzymes expanded
their functions to act in translational and transcriptional
regulation, RNA splicing, and, in higher eukaryotes, signal
transduction pathways [12, 13].
After the discovery of the synthetase-interacting factor,
AIMP1 (also known as p43 and endothelial monocyte
activating protein [EMAP] II), which has broad cell-signal-
ing activities [14, 15], human tyrosyl-tRNA synthetase
(TyrRS) was the first example of a tRNA synthetase having
activities in cell-signaling and angiogenesis [16, 17]. These
activities are manifested when the enzyme is secreted
during an inflammatory response as a procytokine, which
is subsequently activated by natural proteolysis. Later,
more examples further supported the idea of functional
expansion of AARSs in higher eukaryote systems [13,
18]. Human tryptophanyl-tRNA synthetase (TrpRS) is
another example, in which natural fragmentation by either
alternative splicing or proteolysis leads to production of
a potent angiostatic cytokine [19, 20]. The expanded func-
tions of Trp-, Tyr-, and other tRNA synthetases, and of
synthetase-interacting proteins, suggest a broad connec-
tion of translation to signal transduction pathways in
angiogenesis, inflammation, and neuronal development.
Not fully understood, however, is how the cytokine func-
tions of a tRNA synthetase procytokine are activated so
that connections are made to pathways beyond transla-
tion. It is this question—the mechanism of activation of
a synthetase procytokine—that is addressed here.We be-
lieve that this question is closely related to that of under-
standing how dominant, presumptively gain-of-function
mutations might occur in genes for synthetases in the
human population. For this purpose, we focused on TyrRS
as an example in which detailed structural information
could guide our experimental approach.
RESULTS
Background on Structure and Cytokine Activity
of Human TyrRS
TyrRS is a member of the class I tRNA synthetases, which
are characterized in part by a Rossmann fold catalytic33, December 2007 ª2007 Elsevier Ltd All rights reserved 1323
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Cytokine Activation of a Human tRNA SynthetaseFigure 1. Organization of Domains and the ELR Motif of
Human TyrRS
(A) Human TyrRS contains three domains: Rossmann fold catalytic do-
main, anticodon recognition domain, and C domain. The first two
domains constitute mini-TyrRS and are essential for the aminoacyla-
tion of tRNATyr. The C domain is dispensable for aminoacylation.
Mini-TyrRS also has cytokine activity, and an ELR (red) motif in the
Rossmann fold catalytic domain is critical for that activity. C domain
alone also has cytokine activity, and a heptapeptide (red) sequence
close to the N terminus of the C domain was shown to be critical for
its PMN migration activity.
(B) Structure model of full-length TyrRS. The ELR motif (red) on mini-
TyrRS and the heptapeptide (red) on the C domain are likely to be
masked in the full-length protein, where the C domain is linked to
mini-TyrRS.
(C) Analytical gel filtration experiment suggested that the C domain
contributed to the dimer interactions in a way consistent with the struc-
tural model.
(D) The interactions around the ELR motif. Y341 is of special signifi-
cance, as it plays a key role in tethering helix a14 to the ELR.1324 Chemistry & Biology 14, 1323–1333, December 2007 ª20domain with an 11 amino acid signature sequence that
ends in the tetrapeptide, HIGH [21]. In prokaryotes and
lower eukaryotes, the catalytic domain is fused on the
C-terminal side with an anticodon binding domain. This
format—Rossmann fold followed by anticodon binding
domain—is conserved among all TyrRSs in evolution. In
higher eukaryotes, including mammals, an additional
domain, known as the ‘‘C domain,’’ is appended to the
C-terminal side of the anticodon binding domain (Fig-
ure 1A). The C domain, which is homologous to EMAP II
[22], regulates the cytokine activity of TyrRS in a way
that is not understood and is investigated here.
Full-length human TyrRS has no known cytokine activi-
ties. However, when the appended C domain is removed
by natural proteolysis, the remaining mini-TyrRS can
induce migration of polymorphonuclear (PMN) and endo-
thelial cells, and is proangiogenic [16, 17] (the EMAP II-like
C domain of TyrRS is also a procytokine that is activated
when separated from the rest of TyrRS [23]). Removal of
the C domain does not affect aminoacylation activity—
mini-TyrRS charges its cognate tRNA with the same effi-
ciency as the full-length enzyme [16].
An ELR motif embedded in the sequence of mini-TyrRS
was shown by mutational analysis to be critical for its
cytokine activity [16, 23]. An ELR motif is also present in,
and required for, activity of some CXC chemokines,
such as IL-8 [24]. The importance of the ELR motif
for mini-TyrRS is consistent with the observation that
mini-TyrRS binds with high affinity to the IL-8 receptor,
CXCR1 [16]. In earlier work, we separately determined
high-resolution crystal structures of human mini-TyrRS
[25] and of the C domain [26] (embedded in Figure 1B).
The ELR motif was mostly exposed in mini-TyrRS, and
was able, in principle, to interact with a receptor. In con-
trast, in the native, full-length enzyme, we imagine this
motif would be sterically shielded by the C domain.
As for the EMAP II-like C domain, a heptapeptide se-
quence close to the N terminus of the C domain was
shown to be critical for its PMN migration activity [23]. In
our crystal structure of the C domain (embedded in
Figure 1B), this heptapeptide is located on strand b1
(among the seven b strands that form a b-barrel structure),
and is essentially exposed on the surface of the C domain
when that domain is a stand-alone protein. Presumably,
this heptapeptide is also masked in the full-length TyrRS
by mini-TyrRS.
Structural Model of Human TyrRS
While no structure of human TyrRS has been reported,
from the structures of mini-TyrRS and C domain we
were able to build a working model of the full-length pro-
tein (Figure 1B). Mini-TyrRS contains the Rossmann fold
catalytic domain and anticodon recognition domain. It
forms a dimer with the connective peptide (CP) 1 insertion
(in the Rossmann fold domain), forming the dimerization
interface. In the model, the C domain is linked to the C ter-
minus of mini-TyrRS via a flexible loop identified in the
crystal structure of mini-TyrRS [25]. As shown previously,
the surface electrostatic potential of the ELR region in07 Elsevier Ltd All rights reserved
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peptide region in the C domain is negatively charged
[26]. Therefore, the two critical motifs have complementa-
rily charged surfaces that, in principle, can be brought
together for mutual shielding in the full-length TyrRS. If
this is the case, because of the proximity of the ELR motif
to the dimer interface (Figure 1B), the C domain would also
be close to the dimer interface, and could contribute addi-
tional dimerization interactions. Experiments described
below were designed to test whether the C domain
strengthens the dimer interactions.
The dimer interface of mini-TyrRSmainly involves back-
bone H-bonding interactions between residues P159,
L161, and S162 from one subunit, with S137, V140, and
Q142 from the other subunit, and vice versa. We con-
structed a three-residue (P159L160L161) deletion mutant,
designated as D159-161 TyrRS, to disrupt the dimer inter-
action. In contrast to wild-type mini-TyrRS, by analytical
gel filtration chromatography, D159-161 mini-TyrRS was
a monomer (Figure 1C). Thus, the D159-161 deletion suc-
cessfully disrupted dimer formation of mini-TyrRS. We
also created D159-161 TyrRS; that is, the full-length
protein with the same deletion. Significantly, this deletion
did not disrupt dimer formation of full-length TyrRS (both
D159-161 and wild-type TyrRS eluted as dimers from
the gel filtration column [Figure 1C]). These results are
consistent with the C domain being important for provid-
ing dimer stabilization beyond that which comes from
contacts made between partner subunits through the
CP1 insertion. They support the structural model of
dimeric TyrRS having two C domains located near (with
each on one side of) the dimer interface of mini-TyrRS
(Figure 1B).
This model for full-length TyrRS provided the structural
basis to understand the mutual shielding of the cytokine
activities of mini-TyrRS and C domain in the native
enzyme. We reasoned that, if we could specifically re-
move the shield to unmask either of the two critical motifs,
then this AARS procytokine would be converted to a cyto-
kine. To test this hypothesis, we examined the structure to
find a way to ‘‘open’’ that structure, so as to expose the
ELR tripeptide without breaking the covalent polypeptide
backbone. This analysis led to the idea that a specific
point mutation could unhitch a noncovalent tether, and
thereby provide access to ELR and yield a mutant full-
length enzyme that would have the cytokine activities of
mini-TyrRS.
Identification of a Tether that Enables
the C Domain to Shield the ELR Motif
The partially exposed ELR motif of mini-TyrRS is located
within a long a helix (a5) of the Rossmann fold catalytic
domain (Figure 1B). Interestingly, the C-terminal end of
mini-TyrRS, which forms helix a14, is close to the ELR
motif. In fact, a14 is tethered to the ELR motif through
H bonding and stacking interactions that deploy a con-
served tyrosine, Y341, on a14 (Figure 1D). Therefore,
when the C domain is attached to the C-terminal end
of mini-TyrRS, the ELR motif can be easily masked byChemistry & Biology 14, 1323–133the C domain (Figure 1B). We hypothesized that, if we
mutationally disrupted the interactions between the ELR
motif and Y341, then the tether that brings the C domain
into the proximity of the ELR motif would be broken. As
a result, the ELR motif would be exposed, and mini-
TyrRS-like activity would be activated in the full-length
protein.
For this purpose, we constructed a Y341A substitution
to give Y341A TyrRS. The resulting recombinant protein
was stable, so that quantities sufficient for the studies
reported below could be prepared. We also constructed
Y341A mini-TyrRS to use as a control and found it to be
stable. As a further investigation of the conformational
integrity of the two proteins, their aminoacylation activities
were determined. Both Y341A mutants had about 50% of
the aminoacylation activity of the respective wild-type
counterpart (data not shown). This reduction was
expected, because, in the crystal structure of mini-TyrRS,
Y341 makes an H bond to G46, which is an absolutely
conserved residue in the middle of the aforementioned
11 amino acid signature sequence (Figure 1D). That se-
quence motif is important for synthesis and binding of ty-
rosyl-AMP. As expected, the tyrosine-dependent ATP-PPi
exchange activity was significantly reduced for both
Y341A mutant proteins (data not shown). However, possi-
bly because the rate-limiting step in aminoacylation for
many tRNA synthetases is after adenylate synthesis
(transfer of the aminoacyl moiety from AMP to tRNA
[27]), the effect of the Y341A mutation on aminoacylation
activity is not pronounced.
Demonstration of a Broken ‘‘Tether’’ by Protease
Digestion
The Y341A TyrRS mutant proteins were expressed and
purified side-by-side with the previously cloned wild-
type TyrRS. To evaluate whether the Y341A substitution
disrupted the interaction between the ELR motif and helix
a14, proteases were used as probes to detect any subtle
conformational change caused by themutation. We imag-
ined that, with a more opened-up structure, the Y341A
mutant proteins could have additional cleavage site(s)
relative to the wild-type enzyme.
First, we explored protease digestion of wild-type
TyrRS with plasmin and leukocyte elastase, both of which
are extracellular enzymes important for angiogenesis sig-
naling pathways [28, 29]. Plasmin cleaves after accessible
lysines or, occasionally, arginines. Four major fragments
of TyrRS were generated by limited plasmin digestion,
and the identity of each fragment was determined by
mass spectrometry andN-terminal sequencing (Figure 2A,
left). This analysis established that the four fragments
arose from cleavages at three sites, located at K154,
K352, and K356. K154 is a minor cleavage site located
on a long internal loop of the CP1 insertion that splits the
Rossmann nucleotide binding fold (Figure 2B). K352 and
K356 suggest a major cleavage site located on a different
loop—the linker that joins the C domain to mini-TyrRS
(Figure 2B). Therefore, because the major cleavage at
K352 and K356 is within the linker loop, plasmin can3, December 2007 ª2007 Elsevier Ltd All rights reserved 1325
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Cytokine Activation of a Human tRNA SynthetaseFigure 2. Limited Proteolysis of Wild-Type and Y341A TyrRS to Probe for Structural Changes
(A) Additional bands (boxed) were observed with Y341A TyrRS with either plasmin (top) or elastase (bottom) for digestion.
(B) The cleavage sites generated by plasmin (magenta) and elastase (cyan) are marked on the structure. Additional cleavage sites were generated for
Y341A relative to wild-type TyrRS, and those additional sites are located on or near helix a14.liberate mini-TyrRS from the C domain, and thereby acti-
vate the cytokine activities embedded in TyrRS.
Limited elastase cleavage also generated four major
fragments, arising from three cleavages located at V153,
A355, and S366 (Figure 2A, left, and Figure 2B). Although
the sequence specificity of elastase is different than that of
plasmin, the three elastase cleavage sites are essentially
juxtaposed with those of plasmin. This observation—of
the same spatial locations for three distinct cleavage sites
with two different proteases—gave strong confidence that
the protease probes were primarily revealing structural1326 Chemistry & Biology 14, 1323–1333, December 2007 ª200information and not information that was idiosyncratic to
the protease.
When Y341A TyrRS was digested with plasmin, three
fragments in addition to those seen with wild-type TyrRS
were observed. Consistently, elastase also gave addi-
tional cleavage fragments for the Y341A mutant com-
pared to wild-type TyrRS (Figure 2A, right). Those
additional fragments corresponded to Y341A-specific
cleavage sites at K319, K327, and K334 by plasmin, and
L333 and A337 by elastase, respectively. These five addi-
tional cleavage sites are either on helix a14 or at the end of7 Elsevier Ltd All rights reserved
Chemistry & Biology
Cytokine Activation of a Human tRNA Synthetasea13 that connects to a14. This suggests that helix a14,
and part of a13, becomes unwound by virtue of the
Y341A substitution. Most likely, this part of the structure
of the mutant protein is present as a flexible loop, presum-
ably because the tether between a14 and the ELR motif
was broken.
Demonstration of Subtle Structure Opening
by Small-Angle X-Ray Scattering
With the broken tether that holds theCdomain close to the
ELR motif, we imagined that the Y341A mutation would
generate a more extended overall conformation. We
believed that the conformational difference between
Y341A and wild-type TyrRS might be sufficient to be
detected by small-angle X-ray scattering (SAXS). Pur-
suant to this objective, scattering curves were measured
for both wild-type and Y341A human TyrRS at beamline
4-2 at the Stanford Synchrotron Radiation Laboratory.
The radius of gyration (Rg) evaluated by Guinier plots of
the individual scattering curves, recorded at concentra-
tions of 2, 4, 6, 9, and 20 mg/ml, showed no obvious con-
centration dependence, for either the wild-type or the
Y341A enzyme. The Rg values were then extrapolated to
zero concentration, yielding Rg = 46.5 A˚ (±1.0) for the
wild-type and Rg = 49.7 (±1.0) A˚ for the Y341Amutant pro-
tein. These values support the hypothesis that Y341A is
more open, and therefore more extended, than the wild-
type enzyme.
Electron pair distance distribution, P(r), function was
computed with the composite data covering the momen-
tum transfer, Q = 0.01 to 0.25 A˚1, and consisting of the
very small angle portion from the lowest concentration
point (2 mg/ml) and the intermediary angle from either
the 9 or 20mg/ml sample (Figure 3). Themaximum dimen-
sion of the molecule, Dmax = 152 (±3) A˚, was obtained for
the wild-type enzyme, while the Y341A mutant enzyme
gave Dmax = 155 (±5) A˚. The Dmax of our TyrRS model
shown in Figure 1B is about 20 A˚ smaller than the obtained
Figure 3. Electron Pair Distance Distribution Function Gener-
ated by SAXS Experiments for Wild-Type and Y341A TyrRSChemistry & Biology 14, 1323–133Dmax, suggesting that, as the C domain is linked to mini-
TyrRS via the flexible loop, multiple conformations of
TyrRS, including those that are more extended than
our TyrRS model, may be present in solution. Neverthe-
less, a slightly larger Dmax of Y341A TyrRS relative to the
wild-type enzyme is consistent with Y341A TyrRS having
a more opened conformation.
Amore relaxed structure for themutant protein was also
confirmed from the Rg values obtained via P(r): Rg = 47.2
(±0.2) A˚ and Rg = 48.6 (±0.4) A˚ for thewild-type and Y341A
TyrRS, respectively. Interestingly, the P(r) curves of the
wild-type enzyme exhibited two peaks at around 30 and
60 A˚ electron-pair distances (Figure 3). Themutant protein
had a lower, 30 A˚ peak, and a higher, 60 A˚ peak; in addi-
tion, it had an increased distance population between
90 and 140 A˚, indicating that structural domains are likely
to be more spread apart in the case of Y341A TyrRS. The
positions andmagnitudes of the peaks are independent of
the Dmax value used in the analysis. Therefore, these
observations further support the idea of a more open con-
formation for the mutant protein at the level of tertiary
structure.
The Y341A Mutation Confers Angiogenic
Activity to Full-Length TyrRS
The complex process of angiogenesis involves endothe-
lial cell activation, proliferation, and migration. Previous
work established that mini-TyrRS induced chemotaxis
of endothelial cells in vitro and also simulated angiogene-
sis in vivo [17]. To test our hypothesis that the Y341A sub-
stitution activates mini-TyrRS-like activity in full-length
TyrRS, we first tested our mutant protein for stimulation
of endothelial cell proliferation and migration in vitro,
and then went on to test its activity in vivo in two animal
models.
Mini-TyrRS-Like Activity for Y314A TyrRS
in Cell Proliferation and Migration Assays
First, we investigated the stimulation of proliferation of
bovine aortic endothelial cells (BAECs). For these stud-
ies, we used TyrRS, mini-TyrRS, and Y341A TyrRS. We
also used Y341A mini-TyrRS as an additional control.
As expected, mini-TyrRS stimulated the proliferation of
BAECs, while full-length TyrRS did not. In addition, the
Y341A mutation (to give Y341A mini-TyrRS) did not
have much effect on the activity of mini-TyrRS. In con-
trast, the Y341A substitution activated full-length TyrRS
for stimulation of cell proliferation (Figure 4A). The activ-
ity of Y341A TyrRS was comparable to that of mini-
TyrRS.
Similar results were observed in an endothelial cell
migration assay. In these experiments, wounds were cre-
ated in monolayers of human umbilical vein endothelial
cells (HUVECs). Our proteins were added in the media to
test for their activities in wound closure by stimulating
cell migration. Mini-TyrRS closed about 4-fold more area
(Y341A mini-TyrRS closed about 3-fold more area) of the
wound than did the control in 6 hr, whereas full-length
TyrRS closed only slightly more than the control (Fig-
ure 4B). In contrast to TyrRS,Y341ATyrRS, likemini-TyrRS,3, December 2007 ª2007 Elsevier Ltd All rights reserved 1327
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Y341Amutation activated TyrRS, in this case for endothe-
lial cell migration.
Mini-TyrRS-Like Activity for Y314A TyrRS
in Animals
Next, we tested our proteins in vivo in the mouse matrigel
(Figure 5A) and chick chorioallantoic membrane (CAM)
(Figure 5B) assays for angiogenesis. In themousematrigel
model, a collagen plug containing PBS or an added pro-
tein is injected subcutaneously. When there is an added
proangiogenic factor, blood vessels perfuse into the
plug. Upon injection of a fluorescent endothelial cell-
binding lectin, the blood vessel density in each plug can
easily be quantified by spectrophotometric analysis.
As previously reported [17] and confirmed here, in this
model, vascular endothelial growth factor (VEGF) and
mini-TyrRS were both positive for proangiogenic activity
(the Y341A mutation in mini-TyrRS had no effect on its
activity). As expected and as also reported previously
here, full-length TyrRS was inactive in this assay. How-
ever, the Y341A substitution activated TyrRS to give it
an activity in the matrigel assay that was similar to that
seen with mini-TyrRS (Figure 5A).
To confirm the results seen in the matrigel assay, we
further tested the proteins in the CAM assay. Wild-type
TyrRS was inactive, with levels of angiogenesis in the
Figure 4. Endothelial Cell Proliferation and Migration Assays
(A) Y341A mutation activated full-length TyrRS for stimulating prolifer-
ation of BAECs. Cell proliferation was measured in five randomly cho-
sen HPFs by the percentage of cells with positive bromodeoxyuridine
(BrdU) incorporation. Samples were run in triplicate, and mean ± SD is
shown.
(B) Y341A mutation activated full-length TyrRS for stimulating migra-
tion of HUVECs. Migration of untreated monolayers was normalized
to 1. Data from eight experiments were collected for each sample,
and mean ± SD is shown.1328 Chemistry & Biology 14, 1323–1333, December 2007 ª2plug similar to that seen with PBS. However, Y341A TyrRS
was proangiogenic, with an activity similar to that of mini-
TyrRS (Figure 5B). Thus, these data independently sup-
port results from the mouse matrigel assay.
Angiogenic Activity of Y341A TyrRS Not
from Serendipitous Proteolytic Activation
If the Y341A mutation made TyrRS more susceptible to
proteolysis, then the mini-TyrRS fragment of TyrRS might
be serendipitously generated in the above assay systems
that we used to assess activity. In that scenario, the angio-
genic activity we observed with Y341A TyrRSwould come
from proteolytically generated mini-TyrRS. To address
this possibility, we lookedmore closely into our cell migra-
tion assay with HUVECs. We collected and analyzed
media at the 6 hr time point of this assay, when we saw
that only Y341A TyrRS, and not wild-type TyrRS, stimu-
lated wound closure. Using Western blot analysis with
polyclonal anti-TyrRS antibodies, we found that themajor-
ity of the wild-type and Y341A TyrRS proteins were full
length. No more of the mini form was generated from
Y341A than was produced from wild-type TyrRS (Fig-
ure 6A). These results provide no support for the idea that
the activity of Y314A TyrRS is from serendipitous cleavage
of the mutant versus the wild-type version of TyrRS.
Figure 5. Mouse Matrigel and Chick CAM Angiogenesis
Assays
(A) Y341A mutation activated full-length TyrRS for angiogenesis in the
mouse matrigel angiogenesis assay. The blood vessel content in the
matrigel plug with PBS control was normalized to 1. Four mice were
used for separate controls with PBS and VEGF and 6 mice were
used for each of the TyrRS samples. Data shown are mean ± SEM.
(B) Y341A mutation activated the full-length TyrRS for angiogenesis in
chick CAM angiogenesis assay. The plot shows the mean of about 30
measurements for each sample (±SEM).007 Elsevier Ltd All rights reserved
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(A) Less mini form of Y341A TyrRS than of TyrRS was generated in the media during the endothelial cell migration assay, as shown by Western blot
analysis with polyclonal antibody against TyrRS. This observation suggests that the cytokine activation of TyrRS by the Y341A mutation was not a
result of proteolysis.
(B) Time courses of plasmin and elastase digestions of both wild-type and the Y341A TyrRS. The Y341A TyrRS was as stable as the wild-type enzyme
during the digestion. Arrows point to the mini form of TyrRS.In addition, to see if Y341A TyrRS is inherently more
fragile and susceptible to proteolysis, we tested whether
plasmin or elastase could digest Y341A TyrRS more rap-
idly than it digested wild-type TyrRS. Each protein was
incubated with a protease, and the time course of each
digestion was monitored (Figure 6B). Plasmin digested
away both full-length enzymes in 2 hr. For both wild-type
and Y341A TyrRS, the mini form was generated and
cleared after 6 hr (the C domain was more resistant to
plasmin digestion, so that, even at 18 hr, some C domain
remained). An additional band, slightly smaller than that
for mini-TyrRS, was observed in the digestion of Y341A
TyrRS. This band, which was previously identified as
being comprised of residues 1–334 (Figure 2A), remained
in the digestion mixture for more than 6 hr.
Consistently, for elastase digestions, Y341A TyrRS was
cleared no faster than was wild-type TyrRS (Figure 6B) (as
with the plasmin digestion, a fragment slightly smaller than
mini-TyrRS remained for at least 6 hr; this fragment was
identified as comprising residues 1–337 [Figure 2A]).
Thus, with both plasmin and elastase digestions, no evi-
dence for an intrinsically labile and protease-susceptible
fragility of Y341A TyrRS could be obtained. A shorter
form of mini-TyrRS, which can potentially have mini-
TyrRS-like cytokine activity, was generated by each
protease acting on Y341A TyrRS, and was more stable
than mini-TyrRS in the in vitro digestion experiment
(Figure 6B). However, our observation that the amounts
of both mini-TyrRS and the smaller form of mini-TyrRS
were minimal in the media of the HUVEC migration assay
(Figure 6A) is consistent with the proangiogenic activity of
Y341A TyrRS being intrinsic and arising from its having an
accessible ELR motif.Chemistry & Biology 14, 1323–133EMAP II-Like C Domain Not Activated
by Y341A Mutation
The C domain of TyrRS is a homolog of EMAP II, and has
activities for stimulating production of specific cytokines,
and for chemotaxis of leukocytes and monocytes, which
are all masked in native, full-length TyrRS [16]. A hepta-
peptide unit presented on a b barrel is critical for the
chemotaxis activity [23], and this heptapeptide is buried
in the operational model of dimeric human TyrRS, but
exposed on the free monomer unit of the C domain [26].
Our Y341A mutation was designed to produce a subtle
change in conformation that specifically exposed the
ELR motif of the mini-TyrRS portion of TyrRS. Because
of the localized nature of the conformational change, as
supported by the protease digestion study, and the sub-
tlety of the overall conformational change suggested by
SAXS analysis, we imagined that it was unlikely that the
Y341A mutant would affect the region around the critical
heptapeptide of the C domain. Therefore, we expected
that the chemotaxis activity of the C domain would not
be activated by the Y341A mutation.
To further explore this question, we tested the
C-domain activity in a cell migration assay, where only
the C domain, and not native TyrRS and mini-TyrRS, stim-
ulate migration of monocytes. Mononuclear cells were
purified from human blood over a histopaque gradient
and allowed to migrate (in a Boyden chamber assay) un-
der the influence of different concentrations of TyrRS,
Y341ATyrRS, mini-TyrRS, andmini-Y341ATyrRS. EMAP II
and recombinant C domain were used as positive con-
trols, and both caused migration of monocytes in our
assays (Figure 7). As expected, there was nomigration un-
der the influence of TyrRS and mini-TyrRS. Interestingly,3, December 2007 ª2007 Elsevier Ltd All rights reserved 1329
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Each protein (0.1–100 nM) ormedium alonewas
added to the lower compartment of chemotaxis
chambers, and mononuclear cells (105 cells)
were added to the upper compartment. Cham-
bers were incubated for 3 hr, and thenmigrating
cells were counted in five HPFs in each case.
Samples were run in triplicate, and mean ± SD
is shown.Y341ATyrRS also did not stimulate migration of MPs.
Thus, by this functional assay, the critical heptapeptide
unit in the C domain appeared to still be masked in
Y341A TyrRS. In addition, the ‘‘silence’’ of the C domain
in Y341A TyrRS further supports the conclusions from Fig-
ure 6 that serendipitous cleavage of Y341A TyrRS is not
responsible for its cytokine activation.
DISCUSSION
Given that dominant disease-causing mutations occur in
genes for at least two human tRNA synthetases [3, 4],
our work shows how, in principle, such mutations can
occur. That is, for a tRNA synthetase that is also a procyto-
kine, any mutation that serves to bypass the normal cyto-
kine activation pathway (such as alternative splicing or
proteolysis), like a mutation analogous to the Y341A allele
of the gene encoding TyrRS, could, in principle, activate
the embedded cytokine activity and confer a constitutive
gain of function.
Although dominant disease-causing mutations in genes
for human tRNA synthetases are known, the alternative
functions associated with disease are not well under-
stood. For example, point mutations in human TyrRS
and GlyRS are each causally associated with a distinct
autosomal dominant form of Charcot-Marie-Tooth (CMT)
disease [3, 4], the most common heritable peripheral neu-
ropathy. Detailed studies of the aminoacylation activities
of various CMT disease-causing mutant GlyRSs, and of
a genetically constructed mouse model, have established
that CMT disease can occur without defects in aminoacy-
lation activity and, instead, associate the disease to
changes in the dimer interface [10, 11, 30]. These changes
in the dimer interface may affect, via unknown mecha-
nisms, an alternative function of GlyRS that is associated
with neurogenesis.
In the case of TyrRS, the disease-associated mutations
are G41R and E196K, and deletion D153-156VKQV in the
catalytic domain [3]. At least one of these mutant proteins,
E196K, appears to be fully active in aminoacylation.
Because themutations are dominant, they are reminiscent1330 Chemistry & Biology 14, 1323–1333, December 2007 ª20of the work presented here, which demonstrates a muta-
tional gain-of-cytokine function. However, in examining
the locations of the CMT-causing mutations in the struc-
ture of TyrRS, no support could be found for the idea
that the CMT-causing mutations would ‘‘open up’’ the
structure in the way that was seen with the Y341A substi-
tution studied above. Thus, the dominant mutations con-
nected to CMT disease may be unrelated to the cytokine
activation and signaling pathways investigated here. Still,
it remains of interest to test whether the CMT-causing
mutations can be linked in any way to the cytokine activi-
ties known for human TyrRS and, conversely, whether the
Y341A mutation would give rise to a CMT disease-like
condition.
In addition to determining whether a gain-of-function
mutation in a gene for a human tRNA synthetase can be
created, another goal of our work was to understand the
mechanism of activation of synthetase procytokines.
Ourdata showhowsteric shielding-deshielding of a critical
motif embedded within TyrRS can regulate its cytokine
activity. TrpRS, a close homolog of TyrRS, is activated
by alternative splicing or natural proteolysis that removes
a vertebrate-specific N-terminal extension of the polypep-
tide chain [20]. Thus, this extension is thought to regulate
the cytokine activity. When the extension is removed, the
resulting fragment, known as T2-TrpRS, acts through the
VE-cadherin receptor on the surface of endothelial cells
and triggers the Akt signaling pathway [31] (the fragment
has been used in animal models for macular degeneration
and cancer, and in gene therapy applications [19, 32, 33]).
Unlike TyrRS, where the ELR motif embedded in the
catalytic domain has been shown to be critical for the
IL-8-like cytokine activity, the determinants in TrpRS
needed for cytokine activity have not been identified.
However, by analogy to the results presented here, we
speculate that activation of the TrpRS procytokine may
come from steric deshielding of a critical motif embedded
in the core protein. In this instance, the shield would be
provided by the N-terminal extension.
Our work also shows that only subtle changes in struc-
ture are needed for cytokine activation. The protease07 Elsevier Ltd All rights reserved
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ciently sensitive to detect the alteration caused by the
Y341A mutation. At the same time, the change in confor-
mation was small enough that TyrRS was not destabilized
and subjected to proteolysis (Figure 6). This conforma-
tional change has maintained most of the catalytic activity
(see above). When the essential aminoacylation function
and protein stability are both retained, mutations that
activate a cytokine function can be vertically transmitted
and accumulated in the population, where the mutant al-
leles may be associated with a nonlethal pathological con-
dition. That the Y341A TyrRS example shows how cyto-
kine activation can occur, without disruption of stability
or the essential function in protein synthesis, makes plau-
sible the idea that more examples of disease-associated
mutations in genes for tRNA synthetases will be identified
by screening the patient population.
SIGNIFICANCE
Thiswork addresses the question of themechanismof
how an expanded function of a tRNA synthetase is
activated. A proposed model is supported by a series
of biological assays and physical characterizations.
The results also raise new possibilities for under-
standing why mutations in genes for tRNA synthe-
tases are causally linked to human diseases. In this
connection, the work is original in demonstrating the
idea that gain of function can be achieved by mutation
in these enzymes.
EXPERIMENTAL PROCEDURES
Plasmid Construction
Different mutation and deletion constructs of TyrRS were made by
using the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA). Templates were pET20b(+) (Novagen, Madison, WI) vectors
containing the wild-type TyrRS and mini-TyrRS, respectively. Syn-
thetic oligonucleotides were purchased from Invitrogen Corp. (Carls-
bad, CA). All proteins were expressed with a C-terminal His-tag to
facilitate purification.
Protein Production and Endotoxin Removal
Recombinant proteins were expressed in Escherichia coli BL21-Co-
donPlus (DE3)-RIL cells (Stratagene). Cells were grown to an OD600
of 0.8, and induced for 3 hr with 1 mM isopropyl b-D-thiogalactopyra-
noside (Roche, Basel, Switzerland). Cells were pelleted and resus-
pended in buffer A (20 mM Tris-HCl [pH 7.9], 30 mM imidizole,
500mMNaCl). Following lysis by sonication, cell debris was separated
by centrifugation at 74,000 3 g for 30 min. The His-tagged proteins
were purified by Ni-NTA affinity chromatography. Supernatant was
loaded onto a Ni-NTA affinity column (QIAGEN, Valencia, CA), washed
with 100 ml buffer B (buffer A with 0.1% Triton-X114 [Sigma, St. Louis,
MO]) and 150 ml buffer A. Proteins were eluted by a linear gradient of
buffer A and buffer C (20 mM Tris-HCl [pH 7.9], 250 mM imidizole,
500 mM NaCl). Fractions containing greater than 95% pure protein
were pooled, concentrated, and dialyzed into storage buffer (50%
PBS [pH 7.4], 50% glycerol, 2 mM DTT). Proteins used for small angle
X-ray scattering analysis were further purified bymono Q and gel filtra-
tion chromatography. Protein concentration was determined by Brad-
ford assay with the Bio-Rad Protein Assay reagent (Bio-Rad, Hercules,
CA) with bovine serum albumin (Sigma, St. Louis, MO) as a standard.
Endotoxin was removed with EndoTrap Red column (Lonza, Basel,Chemistry & Biology 14, 1323–13Switzerland) from samples used for cell-based assays and the angio-
genesis assays, and endotoxin concentration was determined with
Kinetic-QCL Limulus amebocyte lysate assay (Lonza).
Protease Digestion
Wild-type TyrRS and TyrRS-Y341A were mixed with plasmin or leuko-
cyte elastase at a protein-to-protease ratio of about 32 mg/mg plasmin,
and 2500 mg/U elastase. The mixtures were incubated at 20C for
about 2 hr before the reactions were stopped by addition of formic
acid, to a final concentration of 0.1%. The cleavage fragments in the
mixtures were analyzed by MALDI TOF mass spectrometry and by
N-terminal sequencing with Edman degradation.
SAXS
SAXS measurements were conducted for the wild-type TyrRS and
Y341A TyrRS on beamline 4-2 at the Stanford Synchrotron Radiation
Laboratory. X-ray scattering curves were measured for samples at
various concentrations (2–20 mg/ml). The X-ray wavelength (l) was
1.38 A˚ and the detector channel numbers were converted to the
momentum transfer, Q = 4p 3 sinq/l, where 2 3 q is the scattering
angle. The sample-to-distances of 2.5 m covered Q range 0.01–0.25
A˚1. The polycarbonate cell withmicawindowswas filledwith a sample
aliquot and held at 20C throughout the measurement. A MarCCD165
detector was used throughout the data collection. A typical set of data
collection consisted of 24 two-dimensional scattering images re-
corded in series for 10 s each. A series of data was processed byMar-
Parse [34] along with the matching buffer scattering data, typically
recorded either immediately after or before the protein solution mea-
surement, and scaled for the integrated beam intensity, azimuthally
averaged, inspected for time-dependent changes, which are usually
caused by radiation damage, and subjected to statistical analysis
and averaging. Higher statistical variations of the protein data (1.53)
over the variation of the matching buffer data were allowed in the
averaging. Any data frame that showed a higher level of deviation
with respect to the first protein scattering data frame beyond that level
was rejected. The processed buffer scattering curves were subtracted
from corresponding protein scattering curves after the above data
processing.
The scaling of small- and high-angle data was performed with Pri-
mus [35], which was also used to compute Rg and I (Q = 0) by Guinier
plot in the Q 3 Rg range, 0.45–1.3. P(r) was obtained by the indirect
Fourier transfer of the experimental data by using GNOM [36].
BrdU Proliferation Assay
BAECs (Lonza) were plated onto coverslips precoated with matrigel
(BD Biosciences, Bedford, MA) in EGM-MV (Lonza) and grown until
approximately 75% confluent in a humidified atmosphere with 5%
CO2 at 37
C. Subsequently, cells were washed and placed in DMEM
(Invitrogen) low-serum media supplemented with 0.2% FBS and 1%
penicillin/streptomycin/glutamine solution (Invitrogen) for 24 hr before
treatment with protein samples at a concentration of 1 mM. Cells were
incubated with the proteins for 18 hr and then pulsed with BrdU (Amer-
sham Pharmacia, Piscataway, NJ) for 30 min and fixed in a 4% para-
formaldehyde solution. Proliferating cells were visualized with a pri-
mary rat anti-BrdU antibody (Accurate Chemicals & Scientific Corp.,
Westbury, NY), followed by an anti-rat Alexa-594 secondary
antibody (Invitrogen). Nuclei were stained using DAPI (Invitrogen).
Coverslips were then dried and mounted for analysis by fluorescent
microscopy. Cell proliferation was assessed by counting the number
of BrdU-positive cells in five randomly chosen high-power fields
(HPFs), and expressing this as a mean percentage of the total in these
fields.
Endothelial Cell Migration Assay
HUVECs (Lonza) were plated at a density of about 33 105 cells/well of
a 6-well plate in EGMmedia (Lonza) containing 10% fetal bovine serum
(FBS) and grown to confluent monolayers. Cells were starved in media
without FBS for 16 hr and wounded across the well with a pipette tip.33, December 2007 ª2007 Elsevier Ltd All rights reserved 1331
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to remove cell debris and cells allowed to migrate in the presence of
media alone (negative control) and media containing TyrRS variants
or VEGF (positive control). Images of the wound were taken at 0 and
6 hr after wounding and analyzed with ImageJ (National Institutes of
Health, Bethesda, MD). The percentage of area closed at 6 hr with
respect to the 0 hr area was calculated and used to calculate the
fold migration for each sample over control.
Mononuclear Cell Migration Assay
Human mononuclear cells were prepared from whole blood of normal,
healthy volunteers. Blood was centrifuged (700 3 g) over Histopaque
1077 and 1119 (Sigma). The mononuclear cells so obtained were
washed twice with PBS. The procedure was repeated twice and
the cells resuspended in RPMI 1640 (ATCC, Manassas, VA)
containing heat-inactivated 0.5% FBS (Invitrogen) at a concentration
of 2 3 106 cells/ml.
Cell migration was performed in a microchemotaxis chamber Che-
moTX (Neuro Probe, Gaithersburg, MD) containing polycarbonate
filters (5 mm pores) with polyvinylpyrrolidone (Neuro Probe). A 50 ml
suspension of cells in RPMI 1640 medium containing heat-inactivated
0.5%FBSwas added per well to the upper chamber. Different concen-
trations (0.1–100 nM) of various TyrRS constructs and EMAP II (Pepro-
tech, Rocky Hill, NJ) in RPMI 1640 (0.5% FBS) were added to the lower
chamber, and cells allowed to migrate for 3 hr at 37C in a 5% CO2
incubator. After incubation, nonmigrating cells were removed by
washing the membrane with PBS, and the membrane was fixed in
methanol. Migrated cells were visualized by staining the membrane
with the Diff-Quik stain set (VWR International, West Chester, PA).
Samples were run in triplicate and cells were counted in five HPFs
for each sample.
Murine Matrigel Angiogenesis Assay
Athymic WEHI mice were subcutaneously implanted with 400 ml of
growth factor-depleted Matrigel (Becton Dickinson, Franklin Lakes,
NJ) supplemented with PBS, 20 nM VEGF or 250 nM TyrRS, mini-
TyrRS, Y341A TyrRS, or Y341A mini-TyrRS. Five days later, the mice
were injected intravenously with fluorescein-labeled endothelial bind-
ing lectin Griffonia (Bandeiraea) simplicifolia I, isolectin B4 (GSL-B4)
(Vector Laboratories, Burlingame, CA). Matrigel plugs were resected
and homogenized in radioimmunoprecipitation buffer (10 mM sodium
phosphate, [pH 7.4], 150mMsodium chloride, 1%Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate). Following
homogenization, the fluorescein content of each plug was quantified
by spectrophotometric analysis.
CAM Angiogenesis Assay
ChickCAMangiogenesis assayswere performed at Innovascreen, Inc.
(NewGlasgow, Canada) by the following procedure. Fertilized comple-
ment fixation for avian leukosis virus-negative eggs were incubated for
3.5 days at 38C in 60% humidity. Eggs were then opened and the
embryos were transferred into sterile plastic weigh boats. The em-
bryos were covered and incubated at 37.5C and /90% humidity. After
5 days, collagen/mesh implants containing 30 ml of PBS, VEGF/bFGF
(0.15/0.50 mg), or TyrRS polypeptides (1 mM) were placed onto the
CAM membrane of the embryos and incubated for an additional
72 hr. The upper mesh layers of the implants were examined under
a stereomicroscope and scored for the proportion of ‘‘boxes’’ (i.e.,
three-dimensional regions defined by the mesh fibers) that contain
a blood vessel relative to the total number of boxes.
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